Search results for "FLOX"

showing 10 items of 109 documents

A novel approach to determining physicochemical and absorption properties of 6-fluoroquinolone derivatives: experimental assessment

2002

The ToSS MoDe approach is used to estimate the n-octanol/buffer partition coefficient, the apparent intestinal absorption rate constant and intestinal permeability from a 6-fluoroquinolone data set. Improved in silico methods for predicting a drug's ability to be transported across biological membranes and other biopharmaceutical properties is highly desirable to optimize new drug development. The physicochemical property (Log P) of 26 6-fluoroquinolone derivatives and the absorption properties (Log K(a) and Log P(eff)) of 21 derivatives were well described by the present approach. The models obtained confirm the important role of lipophilicity in the absorption process and its relation wit…

MaleAbsorption (pharmacology)ChemistryAnalytical chemistryPharmaceutical ScienceThermodynamicsGeneral MedicineModels BiologicalIntestinal absorptionRatsPartition coefficientMoment (mathematics)Structure-Activity RelationshipSarafloxacinAnti-Infective AgentsIntestinal AbsorptionMolar refractivityLipophilicityAnimalsRats WistarFluoroquinolonesBiotechnologyAntibacterial agentEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

2005

Abstract The efflux process due to p-glycoprotein-like mechanisms of ciprofloxacin (CIP) and grepafloxacin (GRX) has been studied “in situ” in rats and “in vitro” in Caco-2 cells. The results were modelled by a curve fitting procedure which allowed the characterization of the passive (Pd) and carrier mediated parameters (Vm and Km) from the raw data without initial velocities estimation. CIP absorption in rat was characterized as a passive diffusion at the assayed concentrations. Although the involvement of an efflux transporter cannot be ruled out, its relevance in the transport of the fluoroquinolone is negligible. In GRX absorption, an efflux process is implicated and it is detected in b…

MaleAbsorption (pharmacology)In situCell Membrane PermeabilityPharmaceutical ScienceModels BiologicalPiperazinesDiffusionAnti-Infective AgentsCiprofloxacinIntestine SmallmedicineAnimalsHumansRats WistarAntibacterial agentChemistryTransporterIn vitroGrepafloxacinRatsPerfusionIntestinal AbsorptionBiochemistryPermeability (electromagnetism)BiophysicsEffluxCaco-2 CellsFluoroquinolonesmedicine.drugInternational Journal of Pharmaceutics
researchProduct

Effects of Ethanol on Intestinal Absorption of Drugs

1999

The effect of chronic alcohol intake on the intestinal absorption of seven compounds belonging to a homologous series (ciprofloxacin derivatives) was evaluated using an in situ rat gut technique that measures the intrinsic absorption rates of the compounds both in control and chronic alcohol-fed rats. For chronic alcohol treatment, the animals were fed a liquid diet containing ethanol (36% of calories), whereas an isocaloric diet was given to the pair-fed control animals. The biophysical absorption model, relating the intestinal absorption rate constants and partition indexes of the tested compounds, was then established either for control or alcohol-fed animals. Differences were analyzed a…

MaleAbsorption (pharmacology)Liquid dietEthanolEthanolCentral Nervous System DepressantsMedicine (miscellaneous)PharmacologyToxicologyIntestinal absorptionRatschemistry.chemical_compoundPsychiatry and Mental healthAnti-Infective AgentsIntestinal AbsorptionIntestinal mucosaBiochemistrychemistryPharmacokineticsCiprofloxacinOral administrationAnimalsRats WistarAntibacterial agentAlcoholism: Clinical & Experimental Research
researchProduct

Clinicopathological profile of gastrointestinal tuberculosis: a multinational ID-IRI study

2020

Data are relatively scarce on gastro-intestinal tuberculosis (GITB). Most studies are old and from single centers, or did not include immunosuppressed patients. Thus, we aimed to determine the clinical, radiological, and laboratory profiles of GITB. We included adults with proven GITB treated between 2000 and 2018. Patients were enrolled from 21 referral centers in 8 countries (Belgium, Egypt, France, Italy, Kazakhstan, Saudi Arabia, UK, and Turkey). One hundred four patients were included. Terminal ileum (n = 46, 44.2%), small intestines except terminal ileum (n = 36, 34.6%), colon (n = 29, 27.8%), stomach (n = 6, 5.7%), and perianal (one patient) were the sites of GITB. One-third of all p…

MaleCirrhosismedicine.medical_treatmentretrospective studylaparoscopyColonoscopymultimodal imagingComorbidityGastroenterologyprotionamide0302 clinical medicineLaparotomyAscitesamikacinMedicinebedaquilinePathologie maladies infectieusesintestine biopsyadultsteroidclinical trialGeneral MedicinerifabutinMicrobiologie et protistologie [entomologiephytoparasitolog.]priority journaldiabetes mellitushistopathologybiological productMicrobiology (medical)Microbiologie et protistologie [parasitologie hum. et anim.]medicine.medical_specialtyTuberculosis030106 microbiologymalignant neoplasmArticle03 medical and health scienceslaparotomyHuman immunodeficiency virus infectionmolecular diagnosisHumansTuberculosisGastro-intestinalhumanRetrospective Studiescolondisease predispositionmicrobiologyTuberculosis; Immune-suppression; Gastro-intestinal; Endoscopy;anusmedicine.diseasemajor clinical studymulticenter studyaminosalicylic acidcyclophosphamide0301 basic medicineBiopsyAntitubercular Agentsethambutolrifampicinterminal ileumcolonoscopyofloxacin030212 general & internal medicineLaparoscopyazathioprinemedicine.diagnostic_testIncidence (epidemiology)gastrointestinal tuberculosisDisease Managementchronic kidney failurecycloserineInfectious DiseasesfemaleTreatment OutcomeMolecular Diagnostic Techniquesdiagnostic testDisease Susceptibilitymedicine.symptommoxifloxacinSymptom AssessmentImmune-suppressionstomachisoniazidpyrazinamidestreptomycinliver cirrhosispatient referrallinezolidInternal medicineBiopsybusiness.industryEndoscopyMycobacterium tuberculosishuman tissueclinical featureTreatmentTuberculosis Gastrointestinaltuberculostatic agentbusinessMicrobiologie et protistologie [bacteriol.virolog.mycolog.]
researchProduct

Disposition of ciprofloxacin following intravenous administration in dogs

1994

The pharmacokinetics of ciprofloxacin (CIP) following intravenous administration in dogs have been investigated. The drug was administered at three doses (2.5, 5 and 10 mg/kg body weight) and was assayed in biological fluid samples (plasma and urine) by an HPLC method. The plasma concentration-time curves were best described by a two-compartment open pharmacokinetic model. The drug was widely distributed (Vd(area) almost 3 l/kg), being distributed in the dog more rapidly than in other species (t1/2(lambda 1) 3 min approximately). The elimination half-life (t1/2 lambda 2) was 129-180 min which is similar to values obtained in other species. The unchanged drug eliminated in urine was less tha…

MaleDrugmedia_common.quotation_subjectRenal functionUrinePharmacologyModels BiologicalBiological fluidDogsPharmacokineticsCiprofloxacinmedicineAnimalsChromatography High Pressure Liquidmedia_commonPharmacologyAnalysis of VarianceGeneral VeterinaryChemistryHalf-lifeCiprofloxacinRenal EliminationInjections IntravenousGlomerular Filtration RateHalf-Lifemedicine.drugJournal of Veterinary Pharmacology and Therapeutics
researchProduct

Escherichia coli of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy

2012

Objectives: Poultry have been suggested as a reservoir for fluoroquinolone-resistant extraintestinal pathogenic Escherichia coli (ExPEC). Our aim was to investigate whether genotypes associated with ciprofloxacin and multidrug resistance were shared among human and avian E. coli. Methods: We compared 277 human ExPEC isolates from urinary tract infection (UTI) and sepsis (142 susceptible and 135 ciprofloxacin resistant) and 101 avian isolates (68 susceptible and 33 ciprofloxacin resistant) by antimicrobial resistance phenotype, phylogenetic group and multilocus sequence type (ST). Results: Most ciprofloxacin-resistant isolates from both human and avian sources were multidrug resistant. Human…

MaleMicrobiology (medical)TurkeysSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeBiologymedicine.disease_causeGroup AMicrobiologyAntibiotic resistanceDrug Resistance Multiple BacterialSepsisGenotypeEscherichia colimedicineAnimalsCluster AnalysisHumansPharmacology (medical)zoonosis urinary tract infections MLST molecular epidemiologyChildEscherichia coliEscherichia coli InfectionsPoultry DiseasesPharmacologyExtraintestinal Pathogenic Escherichia coliPhylogenetic treeInfantVirologyDrug Resistance MultipleAnti-Bacterial AgentsCiprofloxacinMultiple drug resistanceInfectious DiseasesItalyChild PreschoolUrinary Tract InfectionsFemaleChickensFluoroquinolonesMultilocus Sequence Typingmedicine.drug
researchProduct

Extended release and enhanced bioavailability of moxifloxacin conjugated with hydrophilic cellulose ethers.

2015

Macromolecular prodrugs (MPDs) of moxifloxacin were fabricated based on hydroxypropylcellulose (HPC) and hydroxyethylcellulose (HEC). UV/Vis spectrophotometry was employed to determine covalently loaded drug content (DC) of each conjugate. The degree of substitution (DS) of moxifloxacin attained ranged from 0.27 to 0.38 (HPC) and 0.19 to 0.26 (HEC) per anhydroglucose unit (AGU), respectively. Transmission electron microscopic analyses showed that HPC-moxifloxacin conjugates self-assembled into nanowires of ∼ 30 nm diameters while HEC-moxifloxacin conjugates self-assembled into nanoparticles of 150-350 nm. In vitro drug release studies revealed that 15 and 49% moxifloxacin release occurred f…

MalePolymers and PlasticsKineticsMoxifloxacinBiological Availability02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundPharmacokineticsMoxifloxacinSpectrophotometryMaterials ChemistrymedicineAnimalsheterocyclic compoundsProdrugsCelluloseCelluloseChromatographymedicine.diagnostic_testOrganic Chemistrybiochemical phenomena metabolism and nutritionProdrugbacterial infections and mycoses021001 nanoscience & nanotechnology0104 chemical sciencesBioavailabilityDrug LiberationKineticschemistryDelayed-Action PreparationsRabbits0210 nano-technologyHydrophobic and Hydrophilic Interactionsmedicine.drugConjugateFluoroquinolonesCarbohydrate polymers
researchProduct

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

2007

Microscopic foci of prostatitis may induce prostate-specific antigen (PSA) increase. PSA reduction after antibiotics might identify those patients in whom biopsy can be avoided. Ninety-nine patients received ciprofloxacin for 3 weeks, of whom 59 showed PSA reduction. Histology detected small foci of prostatitis in 65% of cases. Carcinoma was found in 40 and 20.3% of patients with unchanged or decreased PSA, respectively (P=0.03). No cancer was detected if PSA decreased below 4 ng/ml or more than 70%. Biopsy can be postponed, with a low risk of missing a cancer, if PSA decreases more than 70% or below 4 ng/ml.

MaleRiskCancer Researchmedicine.medical_specialtyTime FactorsProstate biopsymedicine.drug_classUrologyAntibioticsUrologyProstatitisUnnecessary Proceduresurologic and male genital diseasesSettore MED/24 - UrologiaDiagnosis DifferentialProstate cancerCiprofloxacinBiopsyCarcinomaHumansMedicineUltrasonography InterventionalAgedAged 80 and overPalpationmedicine.diagnostic_testbusiness.industryPatient SelectionBiopsy NeedleProstateProstatic NeoplasmsCancerHistologyOrgan SizeMiddle AgedProstate-Specific Antigenmedicine.diseaseAnti-Bacterial AgentsProstatitisOncologybusinessprostate-specific antigen (PSA) prostatitis prostate carcinomaFollow-Up Studies
researchProduct

Prevalence and Risk Factors Associated with Use of QT-Prolonging Drugs in Hospitalized Older People

2016

Aims: The objective of this study was to evaluate the prevalence of the prescription of QT-prolonging drugs at hospital admission and discharge and the risk factors associated with their use in older people (aged 65 years and older). Methods: Data were obtained from the REPOSI (REgistro POliterapie SIMI [Società Italiana di Medicina Interna]) registry, which enrolled 4035 patients in 2008 (n = 1332), 2010 (n = 1380), and 2012 (n = 1323). Multivariable logistic regression was performed to determine the risk factors independently associated with QT-prolonging drug use. QT-prolonging drugs were classified by the risk of Torsades de Pointes (TdP) (definite, possible, or conditional) acc…

MaleTORSADES-DE-POINTES INTERVAL PROLONGATION PATIENT CIPROFLOXACIN COHORT DEATH MULTIMORBIDITY AMIODARONE MORTALITY AIFA.Amiodarone030204 cardiovascular system & hematologyCIPROFLOXACINLogistic regressionAmiodaroneElectrocardiography0302 clinical medicineRisk FactorsTorsades de PointesAtrial Fibrillation80 and overPrevalencePharmacology (medical)030212 general & internal medicineAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalizationmedia_commonAged 80 and overTorsades de PointeAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Pharmacology (medical); Geriatrics and Gerontology; Medicine (all)Medicine (all)DEATHMiddle AgedPatient DischargeHospitalizationLong QT SyndromeCohortHospitalized Older PeopleFemalemedicine.drugHumanDrugmedicine.medical_specialtymedia_common.quotation_subjectMULTIMORBIDITYTorsades de pointesPATIENT03 medical and health sciencesPharmacotherapyInternal medicineINTERVAL PROLONGATIONmedicineHumansTORSADES-DE-POINTESCOHORTMedical prescriptionAIFAAgedbusiness.industryMORTALITYRisk FactorSettore MED/09 - MEDICINA INTERNAOdds ratiomedicine.diseaseQT-Prolonging DrugAged; Aged 80 and over; Amiodarone; Atrial Fibrillation; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Patient Discharge; Prevalence; Risk Factors; Torsades de Pointes; Hospitalization; Geriatrics and Gerontology; Pharmacology (medical)Physical therapyGeriatrics and Gerontologybusiness
researchProduct

The ocular penetration of oral sparfloxacin in humans

1994

The penetration of sparfloxacin into the aqueous humor after oral administration was studied in 28 patients undergoing cataract surgery. Each patient received a single, oral dose of 400 mg of sparfloxacin. In eight other patients scheduled to undergo vitreal surgery, multiple daily oral doses were administered for a total amount of 1,000 mg. The aqueous levels were (mean +/- SEM) 0.127 +/- 0.036 microgram/ml to 0.404 +/- 0.159 microgram/ml from two to 24 hours after ingestion. In the vitreous, the mean drug level was 0.840 microgram/ml (range, 0.480 to 2.060 microgram/ml), from 4.3 to 8.0 hours after the most recent oral dose. Blood samples obtained at the same time as vitreous and aqueous …

Malemedicine.drug_classmedicine.medical_treatment[SDV]Life Sciences [q-bio]AntibioticsAdministration OralCataract ExtractionMicrobial Sensitivity TestsQuinolonesAqueous HumorPharmacokineticsAnti-Infective AgentsOral administrationVitrectomyMedicineIngestionHumansChromatography High Pressure LiquidAntibacterial agentAgedAged 80 and overChemotherapybusiness.industryCataract surgeryMiddle Agedeye diseases[SDV] Life Sciences [q-bio]Vitreous BodyOphthalmologySparfloxacinAnesthesiaFemalesense organsbusinessmedicine.drugFluoroquinolones
researchProduct